Background: Gall Bladder Carcinoma (GBC), an uncommon and aggressive malignancy, is typically detected at a late stage and has a poor prognosis. The usual treatment is gemcitabine and cisplatin, but novel combina-tions like GEMoX, which combines gemcitabine and oxaliplatin, are being tested. This experiment examined GEMOX’s safety and efficacy in advanced GBC. Methods: A retrospective study examined 200 NMCH Patna patients who received GEMOX for advanced GBC between April 2022 and April 2024. The GEMOX regimen consisted of six cycles per 21 days, each involving 1000 mg/m² gemcitabine on Days 1 and 8 and 85 mg/m² oxaliplatin on Day 1. Adverse effects, response rates, PFS, and OS were assessed. Data from medical records was evaluated using SPSS or R. Results: Progress-free survival was 4.5 months (95% CI: 4.0-5.0) and overall survival was 8.7 months (95% CI: 7.9-9.5). Only 5% of patients fully recovered, 35% improved, 40% did not change, and 20% worsened. Stabilisation was 80% and disease control 40%. Most adverse effects were mild to moderate, including 30% neutropenia, 40% nausea/vomiting, and 25% peripheral neuropathy. Patients changed dosage 20% of the time and stopped taking medicine 10% of the time. Conclusion: With acceptable toxicity, GEMOX improves survival in advanced GBC patients. This treatment works well when surgical excision is not possible.

Background: Gall Bladder Carcinoma (GBC), an uncommon and aggressive malignancy, is typically detected at a late stage and has a poor prognosis. The usual treatment is gemcitabine and cisplatin, but novel combina-tions like GEMoX, which combines gemcitabine and oxaliplatin, are being tested. This experiment examined GEMOX’s safety and efficacy in advanced GBC. Methods: A retrospective study examined 200 NMCH Patna patients who received GEMOX for advanced GBC between April 2022 and April 2024. The GEMOX regimen consisted of six cycles per 21 days, each involving 1000 mg/m² gemcitabine on Days 1 and 8 and 85 mg/m² oxaliplatin on Day 1. Adverse effects, response rates, PFS, and OS were assessed. Data from medical records was evaluated using SPSS or R. Results: Progress-free survival was 4.5 months (95% CI: 4.0-5.0) and overall survival was 8.7 months (95% CI: 7.9-9.5). Only 5% of patients fully recovered, 35% improved, 40% did not change, and 20% worsened. Stabilisation was 80% and disease control 40%. Most adverse effects were mild to moderate, including 30% neutropenia, 40% nausea/vomiting, and 25% peripheral neuropathy. Patients changed dosage 20% of the time and stopped taking medicine 10% of the time. Conclusion: With acceptable toxicity, GEMOX improves survival in advanced GBC patients. This treatment works well when surgical excision is not possible.